Six-dog study highlights challenges of M. abscessus in dogs: full analysis

Version 2

A small new retrospective study in the Journal of Small Animal Practice puts a spotlight on Mycobacterium abscessus infection in dogs, describing six confirmed canine cases with either respiratory or cutaneous presentations. The authors report that diagnosis was established with mycobacterial culture and PCR, and that treatment generally relied on clarithromycin-based combinations, but outcomes varied from recovery to relapse and euthanasia. That variability is the headline finding: even when clinicians reach a diagnosis, these infections can be prolonged, difficult to treat, and hard to predict. (merckvetmanual.com)

That matters because M. abscessus sits within a group of rapidly growing nontuberculous mycobacteria that are widely recognized as challenging pathogens. Veterinary reference sources describe mycobacterial disease in companion animals as uncommon, but they also note that members of the chelonae-abscessus group can cause cutaneous lesions in dogs and cats, with pulmonary involvement reported in dogs. In parallel, human infectious disease literature consistently characterizes M. abscessus as difficult to eradicate because of broad innate and acquired antimicrobial resistance. (merckvetmanual.com)

The canine study adds practical clinical detail to that backdrop. According to the abstracted report, the six dogs did not present with a single stereotyped syndrome; instead, some had respiratory manifestations and others had cutaneous disease. That split is useful for clinicians, because it reinforces that mycobacterial infection may surface in more than one service line, including internal medicine, dermatology, and soft tissue workups. The fact that culture and PCR were needed for confirmation also highlights a familiar challenge: these cases can be missed if samples are not specifically submitted for mycobacterial testing. (merckvetmanual.com)

Treatment is another key point. The study reports clarithromycin-based therapy, which is consistent with broader veterinary antimicrobial guidance that places clarithromycin among the drugs considered for M. chelonae/abscessus infections, typically in combination with a second agent guided by culture and susceptibility results. But the same broader literature also warns that clarithromycin resistance may emerge during prolonged therapy in M. abscessus, and human guidance emphasizes that expert consultation is often needed because treatment courses can be long and response inconsistent. In other words, the paper’s mixed outcomes fit with what clinicians would expect from a resistant, slow-to-clear pathogen. (amrvetcollective.com)

Published expert reaction specific to this six-dog paper was limited in open sources, but related veterinary literature points in the same direction. Recent canine case reports involving other mycobacterial species have described long treatment courses, relapse, regimen changes, and the need for multidrug combinations to achieve remission. One recent report on two dogs with Mycobacterium avium infection, for example, documented relapse after an initial clarithromycin-containing regimen in one dog before a revised multidrug protocol produced a response. That doesn’t directly answer how M. abscessus should be managed, but it supports the broader industry view that canine mycobacterial infections often require persistence, repeat assessment, and careful expectation-setting. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinarians, this study is less about changing a guideline overnight and more about sharpening clinical suspicion. Dogs with chronic nodules, draining tracts, nonhealing skin lesions, or respiratory disease that doesn’t behave like routine bacterial infection may warrant earlier consideration of mycobacterial diagnostics. The paper also reinforces the value of obtaining appropriate samples before repeated empiric antibiotic use, both to improve the odds of organism identification and to support antimicrobial stewardship. For pet parents, these are cases where the diagnostic path can be longer and the prognosis more guarded than the initial presentation suggests. (merckvetmanual.com)

There’s also a practical workflow implication for referral and specialty practice. Because diagnosis may require specialized culture handling, PCR, and susceptibility testing, clinicians may need to coordinate closely with diagnostic laboratories and, in some cases, internal medicine or dermatology specialists. The combination of uncommon presentation, organism-level speciation, and potentially prolonged multidrug therapy means these cases can become resource-intensive for both clinics and pet parents. (bsavalibrary.com)

What to watch: The next step will be whether additional case series or institutional reports can identify patterns in breed risk, route of infection, susceptibility profiles, and treatment duration, especially for dogs that relapse after initial improvement. More published veterinary experience could help move the field from case-by-case management toward more standardized diagnostic and therapeutic pathways for rapidly growing mycobacterial infections. (pubmed.ncbi.nlm.nih.gov)